10日8板!金達威(002626.SZZ)創新高 市值突破300億
格隆匯7月22日丨“不老神藥”金達威(002626.SZZ)今日繼續漲,報價49.81元,再創歷史新高,市值達307億元。該股在最近的10個就交易日內收出8個漲停板,累漲88%。其他NMN概念股中,豐原藥業漲超6%,雅本化學漲超5%。金達威暴漲原於7月9日公司董祕在互動平台表示:“在美國工廠生產的Doctor's Best NMN β-煙酰胺單核苷酸NAD抗衰老逆齡,已經上市銷售,天貓旗艦店目前售價1599元/瓶。”該股一時間連收5個漲停板,隨後於7月19日收關注函,公司7月20日迴應關注函稱,對子公司DRB推出的NMN新產品市場前景並不確定,且未來可實現的銷售規模亦不確定,目前不會對公司的經營業績產生影響。迴應發出後股價繼續漲停。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.